MTOR and systemic lupus erythematosus: In addition, increased mTOR activity has been observed in samples from both central and peripheral regions of livedo reticularis skin lesions in aPL-positive systemic lupus erythematosus (SLE) and aPL-positive non-SLE patients [14].